Ikarian Capital’s Kura Oncology KURA Stock Holding History

Ikarian Capital’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-140,000	Closed	-$3.96M	–	252
2021 Q1	$3.96M	Sell	140,000 -145,000	-51%	-$4.59M	0.13%	144
2020 Q4	$9.31M	Buy	285,000 +65,600	+30%	+$2.31M	0.41%	57
2020 Q3	$6.72M	Buy	219,400 +69,400	+46%	+$1.53M	0.49%	54
2020 Q2	$2.44M	Buy	+150,000	New	+$2.16M	0.19%	98

Other funds holding KURA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Ikarian Capital's KURA Position: Q2 2021 in Review

Ikarian Capital sold out of Kura Oncology (KURA) in Q2 2021, closing a stake of 15,603 shares — an estimated $441K sold.

Ikarian Capital first reported a position in KURA in Q1 2020 and held it in 5 quarters. The position peaked at $7.59M in Q2 2020. 171 funds tracked by Wall St. Rank hold KURA as of Q2 2021.

Ikarian Capital reported no remaining Kura Oncology position as of Q2 2021 after selling out during the quarter.
Ikarian Capital sold 15,603 Kura Oncology shares in Q2 2021, an estimated $441K.
Ikarian Capital first reported a position in Kura Oncology in Q1 2020 and held it in 5 quarters.
Ikarian Capital's Kura Oncology position peaked at $7.59M in Q2 2020.
171 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2021.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.